XPOVIO® (Selinexor)

The FDA on July 3, 2019 granted accelerated approval to XPOVIO® in combination with Dexamethasone for adult patients with Relapsed or Refractory Multiple Myeloma (RRMM) who have received at least four prior therapies, and whose disease is refractory to at least two Proteasome Inhibitors, at least two Immunomodulatory agents, and an anti-CD38 monoclonal antibody. XPOVIO® is a product of Karyopharm Therapeutics.